Some products, including tirzepatide and semaglutide injections, lacked essential labeling information, such as active and inactive ingredients, strength, dose, and administration instructions
For patients seeking effective, evidence-based weight management options currently available in the UK, the following licensed treatments may be appropriate depending on individual clinical circumstances: Semaglutide (Wegovy): Licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities, subject to NICE criteria (NICE TA875) Tirzepatide (Mounjaro): Licensed in the UK for type 2 diabetes
Individuals with obesity have distinct microbial communities, often characterized by having an increased ratio of Firmicutes to Bacteroides compared to lean individuals and decreased microbial diversity (98, 102) although these results are not consistent across all studies (105)
If you develop signs of diverticulitis while on semaglutide (sudden abdominal pain, fever, changes in bowel habits, or bloody stools), contact your healthcare provider immediately and pause your medication until cleared by your gastroenterologist
Between 200 and 300 pg/mL is considered borderline
Exercise is not required to lose weight on this diet and only light exercise is permitted